Zhang L, Wei Y, Luo M, Ren S, Zhan X, Wang C
Cell Death Dis. 2025; 16(1):170.
PMID: 40075071
PMC: 11904182.
DOI: 10.1038/s41419-025-07481-8.
Jochems F, Baltira C, MacDonald J, Daniels V, Mathur A, de Gooijer M
Cell Death Differ. 2024; .
PMID: 39706991
DOI: 10.1038/s41418-024-01439-7.
Trembath H, Yeh J, Lopez N
Cancer Treat Res. 2024; 192:305-418.
PMID: 39212927
DOI: 10.1007/978-3-031-61238-1_15.
Jonchere V, Montemont H, Le Scanf E, Siret A, Letourneur Q, Tubacher E
Genome Biol. 2024; 25(1):210.
PMID: 39107855
PMC: 11304650.
DOI: 10.1186/s13059-024-03340-5.
Zhou Y, Tao L, Qiu J, Xu J, Yang X, Zhang Y
Signal Transduct Target Ther. 2024; 9(1):132.
PMID: 38763973
PMC: 11102923.
DOI: 10.1038/s41392-024-01823-2.
Microsatellite instability: A 2024 update.
Yamamoto H, Watanabe Y, Arai H, Umemoto K, Tateishi K, Sunakawa Y
Cancer Sci. 2024; 115(6):1738-1748.
PMID: 38528657
PMC: 11145116.
DOI: 10.1111/cas.16160.
Eukaryotic release factor 1 from Euplotes promotes frameshifting at premature stop codons in human cells.
Stefanov B, Ajuh E, Allen S, Nowacki M
iScience. 2024; 27(4):109413.
PMID: 38510117
PMC: 10952039.
DOI: 10.1016/j.isci.2024.109413.
Chemical modulation of cytosolic BAX homodimer potentiates BAX activation and apoptosis.
Gitego N, Agianian B, Mak O, Kumar Mv V, Cheng E, Gavathiotis E
Nat Commun. 2023; 14(1):8381.
PMID: 38104127
PMC: 10725471.
DOI: 10.1038/s41467-023-44084-3.
The E3 ubiquitin ligase TRIM17 promotes gastric cancer survival and progression via controlling BAX stability and antagonizing apoptosis.
Shen J, Yang H, Qiao X, Chen Y, Zheng L, Lin J
Cell Death Differ. 2023; 30(10):2322-2335.
PMID: 37697039
PMC: 10589321.
DOI: 10.1038/s41418-023-01221-1.
Eltrombopag directly activates BAK and induces apoptosis.
Chen M, Hu L, Bao X, Ye K, Li Y, Zhang Z
Cell Death Dis. 2023; 14(7):394.
PMID: 37393297
PMC: 10314921.
DOI: 10.1038/s41419-023-05918-6.
Promoter hypermethylation and comprehensive regulation of ncRNA lead to the down-regulation of ZNF880, providing a new insight for the therapeutics and research of colorectal cancer.
Dong X, Zhang Y, Sun Y, Nan Q, Li M, Ma L
BMC Med Genomics. 2023; 16(1):148.
PMID: 37370088
PMC: 10294494.
DOI: 10.1186/s12920-023-01571-2.
Co-Delivery System of Curcumin and Colchicine Using Functionalized Mesoporous Silica Nanoparticles Promotes Anticancer and Apoptosis Effects.
AbouAitah K, Soliman A, Swiderska-Sroda A, Nassrallah A, Smalc-Koziorowska J, Gierlotka S
Pharmaceutics. 2022; 14(12).
PMID: 36559264
PMC: 9785757.
DOI: 10.3390/pharmaceutics14122770.
Mitochondrial Dysfunction: Pathophysiology and Mitochondria-Targeted Drug Delivery Approaches.
Khan T, Waseem R, Zehra Z, Aiman A, Bhardwaj P, Ansari J
Pharmaceutics. 2022; 14(12).
PMID: 36559149
PMC: 9785072.
DOI: 10.3390/pharmaceutics14122657.
Strong Hereditary Predispositions to Colorectal Cancer.
Hryhorowicz S, Kaczmarek-Rys M, Lis-Tanas E, Porowski J, Szuman M, Grot N
Genes (Basel). 2022; 13(12).
PMID: 36553592
PMC: 9777620.
DOI: 10.3390/genes13122326.
The distinct clinical trajectory, metastatic sites, and immunobiology of microsatellite-instability-high cancers.
Han S, Chok A, Peh D, Ho J, Tan E, Koo S
Front Genet. 2022; 13:933475.
PMID: 36531239
PMC: 9751431.
DOI: 10.3389/fgene.2022.933475.
Harnessing TRAIL-induced cell death for cancer therapy: a long walk with thrilling discoveries.
Montinaro A, Walczak H
Cell Death Differ. 2022; 30(2):237-249.
PMID: 36195672
PMC: 9950482.
DOI: 10.1038/s41418-022-01059-z.
The "Yin and Yang" of Unfolded Protein Response in Cancer and Immunogenic Cell Death.
Rufo N, Yang Y, de Vleeschouwer S, Agostinis P
Cells. 2022; 11(18).
PMID: 36139473
PMC: 9497201.
DOI: 10.3390/cells11182899.
Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies.
Thomalla D, Beckmann L, Grimm C, Oliverio M, Meder L, Herling C
Blood. 2022; 140(20):2113-2126.
PMID: 35704690
PMC: 10653032.
DOI: 10.1182/blood.2021014304.
Emerging actionable targets to treat therapy-resistant colorectal cancers.
Grassilli E, Cerrito M
Cancer Drug Resist. 2022; 5(1):36-63.
PMID: 35582524
PMC: 8992594.
DOI: 10.20517/cdr.2021.96.
The BCL-2 family member BOK promotes KRAS-driven lung cancer progression in a p53-dependent manner.
Meinhardt A, Munkhbaatar E, Hockendorf U, Dietzen M, Dechant M, Anton M
Oncogene. 2022; 41(9):1376-1382.
PMID: 35091677
PMC: 8881215.
DOI: 10.1038/s41388-021-02161-1.